Mewissen Mark W
Vascular Center, St. Luke's Medical Center, 2801 W. Kinnickinnic River Parkway, Suite 514, Milwaukee, WI 53215, USA.
J Endovasc Ther. 2009 Apr;16(2 Suppl 2):II63-81. doi: 10.1583/08-2658.1.
The 1- to 2-year primary patency rates associated with self-expanding nitinol stents for the treatment of symptomatic femoropopliteal disease are superior to those for percutaneous transluminal angioplasty (PTA) and the first-generation stainless steel balloon-expandable stents. The advantages of nitinol stents include improved radial strength and flexibility, the ability to recover from being crushed, reduced foreshortening, and (importantly) deployability without balloon dilation of the stent edge (which may decrease the incidence of the edge stenosis, or "candy-wrap" effect, often observed with balloon-expandable stents). The technical success rate associated with primary deployment of nitinol stents is very high, and acute to 6-month patency results are predictably excellent. Prior to the introduction of nitinol stents, the original guidelines (2000) of the multidisciplinary TransAtlantic Inter-Society Consensus (TASC I) recommended only an adjunctive role for femoropopliteal stents following suboptimal PTA. The abbreviated 2007 TASC II report essentially extended this recommendation to nitinol stents. Here, current trials of nitinol stenting in the femoropopliteal segment are discussed, with emphasis on the advantages of primary (and often direct) deployment in selected circumstances dependent on factors including lesion length, lesion location, indication for treatment (critical limb ischemia or claudication, in-stent restenosis, stent-graft restenosis), and the relative appropriateness of other modalities (e.g., covered stents). Technical considerations in primary nitinol stenting are briefly reviewed. Open questions regarding the factors involved in nitinol stent fracture and the possible association of fracture and restenosis are examined in the context of current clinical trials. A new generation of femoropopliteal nitinol stents combining superior durability and flexibility is expected soon. Development and implementation of uniform reporting and surveillance standards is important for optimizing current and future research.
用于治疗有症状的股腘动脉疾病的自膨式镍钛合金支架,其1至2年的初始通畅率优于经皮腔内血管成形术(PTA)和第一代不锈钢球囊扩张式支架。镍钛合金支架的优点包括径向强度和柔韧性提高、受压后可恢复原状、缩短程度降低,以及(重要的是)无需球囊扩张支架边缘即可展开(这可能会降低边缘狭窄或“糖纸”效应的发生率,而这种效应在球囊扩张式支架中经常出现)。镍钛合金支架初次植入的技术成功率非常高,急性至6个月的通畅结果可预见地良好。在镍钛合金支架引入之前,多学科跨大西洋协作组共识(TASC I,2000年)的原始指南仅建议在PTA效果欠佳后,股腘动脉支架起辅助作用。2007年TASC II的简要报告基本上将这一建议扩展到了镍钛合金支架。在此,讨论了当前镍钛合金支架在股腘动脉段的试验情况,重点是在某些特定情况下进行初次(通常是直接)植入的优势,这些情况取决于病变长度、病变位置、治疗指征(严重肢体缺血或间歇性跛行、支架内再狭窄、覆膜支架再狭窄)以及其他治疗方式(如覆膜支架)的相对适用性。简要回顾了镍钛合金支架初次植入的技术要点。在当前临床试验的背景下,探讨了有关镍钛合金支架断裂相关因素以及断裂与再狭窄可能关联的一些未解决问题。预计新一代兼具卓越耐用性和柔韧性的股腘动脉镍钛合金支架即将问世。制定和实施统一的报告及监测标准对于优化当前和未来的研究很重要。